Alectinib targets and binds to the ALK protein, preventing it from sending growth signals to cancer cells. This action inhibits the proliferation of cancer cells and induces cell death. Alectinib is particularly effective in cases where cancer has developed resistance to other ALK inhibitors, such as crizotinib.
